De-escalation of axillary surgery in clinically node-negative (cN0) breast cancer: current evidence, advances, and controversies
4 affiliations
- 1Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China
- 2Department of General Practice, The First Hospital of Jilin University, Changchun, China
- 3The Second Department of Gynecologic Oncology, Jilin Cancer Hospital, Changchun, Jilin, China
- 4Department of Burn and Plastic Surgery, Jilin Provincial People’s Hospital, Changchun, Jilin, China
Abstract
Clinically node-negative (cN0) breast cancer accounts for a large proportion of newly diagnosed cases, and its axillary management is undergoing a paradigm shift toward de-escalation aimed at minimizing surgical morbidity. Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for nodal staging in cN0 disease, and subsequent trials have questioned the need for completion ALND in selected SLN-positive patients. This narrative review summarizes two decades of pivotal trial evidence across three conceptually distinct de-escalation strategies, which differ in their levels of evidence. First, phase III randomized evidence supports omission of ALND after a positive SLNB for isolated tumor cells and micrometastases (IBCSG 23-01; 10-year disease-free survival HR 0.85, with the non-inferiority criterion met), and for 1–2 macrometastases when combined with breast-conserving surgery and radiotherapy (ACOSOG Z0011, AMAROS, SENOMAC). Second, omission of SLNB itself has demonstrated 5-year oncological safety in rigorously selected low-risk patients with small tumors and negative preoperative axillary ultrasonography (SOUND, INSEMA), in cohorts that were predominantly HR-positive/HER2-negative. Third, emerging strategies, such as advanced imaging, ctDNA-based monitoring, and AI-assisted diagnostics, may further refine patient selection but remain investigational and are not part of established clinical practice at present. The current evidence is insufficient to support routine de-escalation in HER2-positive and triple-negative disease or in other populations underrepresented in the pivotal trials. Axillary de-escalation is therefore justified only within the specific clinical scenarios validated by randomized trials, and aggressive subtypes and biomarker-guided strategies require further prospective evidence before integration into clinical practice.
Related
- National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer.
- Risk Stratification and Surgical De-Escalation in T1 Invasive Lobular Carcinoma: A Retrospective Analysis of Preoperative Axillary Imaging
- [18F]FDG PET/CT-Derived Metabolic Characteristics and Tumour-Infiltrating Lymphocytes for Predicting Axillary Response to Neoadjuvant Chemo-(Immuno)Therapy in Clinically Node-Positive Breast Cancer
- Multifocal FDG-avid pancreatic pseudomasses mimicking metastases during pembrolizumab for axillary recurrence of triple-negative breast cancer: a case report of immune-related pancreatitis
- Characterization and Antimicrobial Susceptibility Patterns of Clinically Significant Non-fermenting Gram-Negative Bacilli Isolated From Clinical Specimens
BibTeX
@article{ma2026deescalation,
title = {{De-escalation of axillary surgery in clinically node-negative (cN0) breast cancer: current evidence, advances, and controversies}},
author = {Jinxiu Ma and Meizi Cui and Dongqing Li and Sijia Wang and Jian Sun and Hao Guo and Yingying Ding and Zhimin Fan and Xiaozhen Wang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1971201},
url = {https://doi.org/10.3389/fonc.2026.1971201},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - De-escalation of axillary surgery in clinically node-negative (cN0) breast cancer: current evidence, advances, and controversies
AU - Jinxiu Ma
AU - Meizi Cui
AU - Dongqing Li
AU - Sijia Wang
AU - Jian Sun
AU - Hao Guo
AU - Yingying Ding
AU - Zhimin Fan
AU - Xiaozhen Wang
PY - 2026
DA - 2026/10/12
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1971201
UR - https://doi.org/10.3389/fonc.2026.1971201
AB - Clinically node-negative (cN0) breast cancer accounts for a large proportion of newly diagnosed cases, and its axillary management is undergoing a paradigm shift toward de-escalation aimed at minimizing surgical morbidity. Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for nodal staging in cN0 disease, and subsequent trials have questioned the need for completion ALND in selected SLN-positive patients. This narrative review summarizes two decades of pivotal trial evidence across three conceptually distinct de-escalation strategies, which differ in their levels of evidence. First, phase III randomized evidence supports omission of ALND after a positive SLNB for isolated tumor cells and micrometastases (IBCSG 23-01; 10-year disease-free survival HR 0.85, with the non-inferiority criterion met), and for 1–2 macrometastases when combined with breast-conserving surgery and radiotherapy (ACOSOG Z0011, AMAROS, SENOMAC). Second, omission of SLNB itself has demonstrated 5-year oncological safety in rigorously selected low-risk patients with small tumors and negative preoperative axillary ultrasonography (SOUND, INSEMA), in cohorts that were predominantly HR-positive/HER2-negative. Third, emerging strategies, such as advanced imaging, ctDNA-based monitoring, and AI-assisted diagnostics, may further refine patient selection but remain investigational and are not part of established clinical practice at present. The current evidence is insufficient to support routine de-escalation in HER2-positive and triple-negative disease or in other populations underrepresented in the pivotal trials. Axillary de-escalation is therefore justified only within the specific clinical scenarios validated by randomized trials, and aggressive subtypes and biomarker-guided strategies require further prospective evidence before integration into clinical practice.
SN - 2234-943X
ER -